| 1.46 0.14 (10.61%) | 02-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.49 | 1-year : | 7.98 |
| Resists | First : | 4.7 | Second : | 6.84 |
| Pivot price | 1.73  |
|||
| Supports | First : | 1.25 | Second : | 1.04 |
| MAs | MA(5) : | 1.53 |
MA(20) : | 2.08 |
| MA(100) : | 7.69 |
MA(250) : | 27.97 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 11.5 |
D(3) : | 10.4 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 632 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ASBP ] has closed above bottom band by 22.2%. Bollinger Bands are 84.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.49 - 1.5 | 1.5 - 1.51 |
| Low: | 1.24 - 1.25 | 1.25 - 1.26 |
| Close: | 1.44 - 1.46 | 1.46 - 1.48 |
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Wed, 04 Feb 2026
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - The Times-Mail
Tue, 03 Feb 2026
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Journal & Courier
Tue, 03 Feb 2026
Aspire Biopharma Provides Q3 2025 Business Update - Journal & Courier
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 2.29e+006 (%) |
| Held by Institutions | 10.8 (%) |
| Shares Short | 338 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -59 % |
| Return on Assets (ttm) | 15.8 % |
| Return on Equity (ttm) | -195.2 % |
| Qtrly Rev. Growth | 1940 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 1078.04 |
| Qtrly Earnings Growth | -37.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.13 |
| Dividend | 0 |
| Forward Dividend | 729170 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|